Search Results for “EC” – Page 185 – media

$2.2 billion settlement, GSK pays for safety

Zantac was originally a popular heartburn drug. From being popular all over the world to being withdrawn from the market due to carcinogenic risks, the years-long litigation disputes can be regarded as a slow and bumpy roller coaster for patients and manufacturers. This storm can be traced back to June 2019. At that time, Valisure discovered and informed the FDA during routine batch testing that the active ingredient ranitidine in Zantac would degrade under certain conditions and produce N-nitrosodimethylamine (NDMA), a Class 2A carcinogen. In September of the same year, Valisure formally submitted a citizen petition to the FDA, requesting the recall of all products containing ranitidine. Since then, Zantac has been deeply involved in the carcinogenic storm. The FDA further found that the higher the storage temperature or the longer the storage time of Zantac, the higher the risk of exceeding the standard of NDMA, which was originally very ...
- Source: drugdu
- 67
- October 14, 2024
A tumultuous time for the king of orphan drugs

More than 20 years ago, research on rare diseases and the treatment of rare diseases were very rare in the medical community. The small market size of rare diseases and the huge difficulty in research and development have made pharmaceutical companies shy away from this field. In the past 25 years, BioMarin has launched eight rare disease drugs with strong R&D capabilities. Arguably, this record is unmatched by few companies in the biotech industry. However, with the failure of the commercialization of its highly-anticipated hemophilia A gene therapy, Roctavian, a strategic review began. Since the beginning of this year, BioMarin has been in turmoil. Over the past nine months, there have been layoffs, executive restructuring, spending cuts, and research projects on hold. With the reshuffle of the business structure and the arrival of new competition, it remains to be seen when BioMarin will be able to get out of this ...
- Source: drugdu
- 64
- October 14, 2024
Dental laser equipment boss, bankruptcy and acquisition

On October 9, 2024, Biolase, which occupies the top spot in the world’s dental laser equipment, announced that it has signed an agreement to sell the majority of the company’s assets to rival Sonendo for $14 million. Biolase Company of United States, the world’s leading oral laser expert, has long been committed to the research and development and manufacturing of full-function lasers, with a global laser market share of 70%. However, due to long-term losses, the stock price continued to be depressed, and it was delisted from the Nasdaq in June this year and declared bankruptcy on October 1. The buyer of the acquisition, Sonendo, a dental giant dedicated to root canal treatment devices, sued Biolase in 2023 for a patent dispute, claiming no less than $59 million in damages. This acquisition not only marks the end of an era for the giant Biolase, but also announces the end of ...
- Source: drugdu
- 59
- October 14, 2024
Nationally sourced intraocular lenses, who is the winner?

On August 30, 2024, the Shanghai Pharmaceutical Affairs Institute issued a document that the information on products related to the centralized procurement of intraocular lenses and sports medicine organized by the state will be released through the portal on September 3, 2024, and will take effect on September 10, 2024. So far, the fourth batch of national procurement has been implemented in all provinces across the country. The “Notice on the Centralized Procurement and Use of Intraocular Lens and Sports Medicine Medical Consumables Organized by the State” issued by Shanghai marks the full implementation of the fourth batch of high-value consumables in China. This policy has had a significant impact on the medical industry, especially on the intraocular lens market. It is reported that 126 companies were selected in this national procurement, involving 30 product categories, and the average price reduction of the selected products was 70%, of which the ...
- Source: drugdu
- 58
- October 14, 2024
intensified BD trading competition in the pharmaceutical market, pharmaceutical companies launch market competition war

Source: 21st Century Business Herald Has the cow arrived? The A-share market is booming, don’t miss the opportunity, open an account and layout now>> Recently, there has been a frequent wave of business development (BD) cooperation transactions between Chinese and foreign pharmaceutical companies. On October 9th, Baiaotai announced that it has reached an authorization license, production, supply, and commercialization agreement with Gedeon Richter Plc. for BAT2206 (ustekinumab) injection solution. According to the agreement, Baiaotai will license the exclusive commercial rights of the injection in the EU, UK, Switzerland, Australia, and other European markets to Gedeon Richter Plc for a fee. The amount involved in this transaction includes a down payment of $8.5 million, milestone payments up to a cumulative total of $101.5 million, and revenue sharing based on a double-digit percentage of net sales. In addition to Baiaotai, several Chinese pharmaceutical companies have also recently received positive news regarding BD ...
- Source: drugdu
- 80
- October 12, 2024
14.1 billion, Johnson&Johnson announces big move

On October 9th, Johnson&Johnson announced plans to invest over $2 billion (approximately RMB 14.1 billion) in Wilson, North Carolina to build an advanced biopharmaceutical manufacturing facility to support its growing portfolio of biologic therapy products in oncology, immunology, and neuroscience. It is reported that this measure is in line with Johnson&Johnson’s broader strategy of submitting or launching over 70 new therapies and product expansions by the end of the next decade. The new facility will be equipped with cutting-edge technology, which will not only enhance global production capacity, but also provide approximately 420 high skilled full-time positions for the local area. The project will begin construction in the first half of 2025. In August of this year, in order to strengthen its position in the cardiovascular field, Johnson&Johnson announced the acquisition of V-Wave, a company specializing in heart failure treatment technology. Prior to this, Johnson&Johnson acquired for approximately $13.1 billion ...
- Source: drugdu
- 70
- October 12, 2024
Dental laser equipment leader, bankrupt and acquired

On October 9, 2024, Biolase, which dominates the global dental laser equipment market, announced that it has signed an agreement to sell most of its assets to competitor Sonendo for $14 million. Biolase, a leading dental laser expert in the world, has long been committed to the research and manufacturing of fully functional lasers, with a global laser market share of 70%. But due to long-term losses, the stock price remained low, and it was delisted from NASDAQ in June this year, and declared bankruptcy on October 1st. The buyer of this acquisition case, Sonendo, is a dental giant dedicated to root canal treatment equipment. Its subsidiary sued Biolase in 2023 for a patent dispute and demanded compensation of no less than $59 million. This acquisition not only marks the end of an era for giant Biolase, but also declares the end of the aforementioned patent dispute. 01. The world’s ...
- Source: drugdu
- 75
- October 12, 2024
Twinings Biopharmaceuticals, Lingrui, Hisun…

As of the first three quarters, there were 9 pharmaceutical stocks with a market value of 100 billion yuan, with Mindray Medical firmly in the top spot and Hengrui Medicine returning to a market value of 300 billion yuan. In terms of quantity, there were 4 more stocks compared with the first half of the year, with Aier Eye Hospital, Yunnan Baiyao, United Imaging Healthcare, and Wantai Biopharma returning to the 100 billion yuan market value echelon. Among the TOP20, 15 stocks have positive growth, with Hengrui Medicine, BeiGene, Yunnan Baiyao, Shanghai Pharmaceuticals, China Resources Sanjiu, Baili Tianheng and 10 other stocks growing at a rate of more than 10%; while in the first half of the year, only 6 stocks had positive growth, with 4 other stocks growing at a rate of more than 10%, including Shanghai Pharmaceuticals and China Resources Sanjiu. Mindray Medical has firmly established itself as ...
- Source: drugdu
- 72
- October 12, 2024
A major pharmaceutical province issued a document to dig deep into medical corruption

In May this year, the National Health Commission and 14 other departments issued the “Notice on Printing and Distributing the Key Points for Correcting Unhealthy Trends in the Field of Pharmaceutical Purchase and Sale and Medical Services in 2024”, which includes 5 parts and 15 items. The local level has also successively issued the key points for correcting unhealthy trends in 2024. Judging from the above-mentioned “Notice” issued by Shanghai, the key points for Shanghai’s corrective work in 2024 are basically consistent with the national documents, and some new content has also been added, totaling 5 parts and 18 items. The “Notice” clearly states that the city’s centralized rectification of corruption in the pharmaceutical field and the centralized rectification of unhealthy trends and corruption around the masses should be carried out in a coordinated manner, and the construction of systems in the field of pharmaceutical purchase and sale should be ...
- Source: drugdu
- 74
- October 12, 2024
Drugdu.com Shines at CPhI Milan 2024

▲October 2024, CPhI Milan On October 10, 2024, the highly anticipated CPhI Milan event concluded in Italy, leaving behind a lasting impression. Drugdu.com, a global leader in cross-border pharmaceutical B2B platforms, stood out with its innovative digital solutions and accurate buyer-supplier matching services, garnering widespread attention from the global pharmaceutical community. ▲Drugdu.com at the CPhI Milan show in October 2024 Platform Highlights: Smart Cross-Border Trade Services At the event, Drugdu.com demonstrated its leading smart supply-demand matching feature, allowing buyers to effortlessly post procurement needs and swiftly connect with high-quality global suppliers. The platform’s real-time, efficient negotiations boosted transaction success, with many participants leveraging its capabilities to finalize collaborations during the exhibition. Additionally, Drugdu.com provided VIP members with customized promotion strategies, offering exclusive brand exposure and diverse inquiry channels to help businesses expand their global market presence. Advancing Digital Pharmaceutical Trade Beyond being a platform, Drugdu.com is committed to advancing the digitalization ...
- Source: drugdu
- 69
- October 11, 2024

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.